Business Context and Reporting Period
Company: Silver Spike Investment Corp. (SSIC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2022
Business Overview: SSIC is an externally managed, closed-end, non-diversified Business Development Company (BDC) and Regulated Investment Company (RIC). The company focuses on investing in the cannabis ecosystem, primarily through secured debt, unsecured debt, and equity-related investments in private leveraged middle-market cannabis companies. The company completed its initial public offering (IPO) in February 2022.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 |
|---|---|---|
| Total Investment Income | $809,591 | $0 |
| Total Expenses | $588,346 | $164,062 |
| Net Investment Income | $221,245 | $(164,062) |
| Net Increase in Net Assets from Operations | $211,737 | $(164,062) |
| Cash and Cash Equivalents | $60,618,447 | $5,400 |
| Total Assets | $85,309,286 | $85,031,787 (Note: Prior period assets were primarily cash) |
| Total Liabilities | $545,459 | $479,697 |
| Net Asset Value (NAV) per Share | $13.64 | $13.61 |
| Portfolio Investments (Fair Value) | $24,417,500 | $0 |
Material Changes vs. Prior Period
- Portfolio Deployment: The company transitioned from a pre-investment phase to active deployment. As of March 31, 2022, the company held no portfolio investments. By June 30, 2022, it had invested approximately $24.4 million in two portfolio companies (Shryne Group, Inc. and PharmaCann, Inc.).
- Revenue Generation: Investment income increased from $0 in the prior year to $809,591, driven by $399,591 in interest income and $410,000 in fee income (structuring fees).
- Profitability: The company moved from a net investment loss of $(164,062) in the prior period (driven by organizational expenses) to a net investment income of $221,245.
- Cash Position: Cash and cash equivalents decreased from $84.8 million to $60.6 million, reflecting the deployment of capital into the initial portfolio.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management maintains an active pipeline of over $1.25 billion in potential investments. The company targets a debt-to-equity ratio of 0.50x and intends to utilize leverage in the future if returns exceed borrowing costs.
- Market Risk: The portfolio is sensitive to interest rate changes. Approximately 83.2% of debt investments are floating-rate (based on PRIME), while 16.8% are fixed-rate. A 100 basis point increase in the Prime rate would increase net income by approximately $210,000 annually.
- Credit Risk: All current investments are rated "Grade 2" (performing in-line with expectations). There are no loans on non-accrual status.
- Regulatory Risk: The company operates in the cannabis sector, which faces significant regulatory uncertainty at the federal level in the U.S. Certain assets (e.g., cannabis licenses) may not be usable as collateral under state laws.
- Unusual Items: The $410,000 in fee income is non-recurring, related to structuring fees from the initial investments.
Investor Verification Checklist
- Portfolio Concentration: Verify the financial health of the two portfolio companies (Shryne Group and PharmaCann), which represent 100% of the current investment portfolio.
- NAV Discount: Note that as of August 9, 2022, the stock traded at approximately $9.31, representing a significant discount (approx. 31.7%) to the NAV of $13.64.
- Related Party Transactions: Review the Investment Advisory Agreement with Silver Spike Capital, LLC (SSC), which holds approximately 72% of voting stock and receives a 1.75% base management fee plus incentive fees.
- Capital Deployment Speed: Monitor the company's ability to deploy the remaining ~$60 million in cash into the pipeline to generate yield and reduce the drag of uninvested cash on returns.
- Regulatory Compliance: Confirm ongoing compliance with RIC tax requirements (distributing 90% of taxable income) to avoid corporate-level taxation.